Visen Pharma (Ticker: 2561 HK), a late-stage biopharmaceutical company focused on endocrinology treatments in China (including Hong Kong, Macau, and Taiwan), and plans to list on the Hong Kong Stock Exchange on March 21, 2025. The IPO offering is for 9.9 million shares at an offer price range of HKD 68.44 - 75.28, with aims to raise approximately between HKD 677.56 - 745.27 million (around USD 92 million). The company has one core product, lonapegsomatropin (a once-weekly growth hormone for pediatric growth hormone deficiency, or PGHD) and two other pipeline drugs, TransCon CNP (for achondroplasia) and palopegteriparatide (for hypoparathyroidism). The IPO Proceeds will be used to develop their pipeline of drugs. Key underwriters include Jefferies Hong Kong Limited and Morgan Stanley Asia Limited. The indicated market cap range is approximately USD 1 billion.